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Biotechnology in Agricultural 
Policies of Sub-Saharan Africa
Joel W. Ochieng and Anthony Ananga
Abstract
The agricultural policy environment in sub-Saharan Africa in the last 15 years 
has been erratic, especially with regard to adoption of biotechnology. While many 
biotech products such as tissue culture (TC) banana, hybrid maize, and others 
are now frequent at farm level, the adoption of some of the technologies remains 
relatively low, partly due to political and regulatory bottlenecks that have ham-
pered farm deployment and entry into market systems of genetically engineered 
crops and products. This chapter reviews the political landscape of biotech crops 
across sub-Saharan Africa; analyses the state of enabling policy environment in 
key countries; discusses the impact of push-pull factors on food security, research, 
and training; and identifies the opportunities for investment in biotechnology and 
agribusiness in sub-Saharan Africa.
Keywords: biotechnology, policy environment, Africa, agriculture, GMO, adoption, 
regulation
1. Introduction
Sub-Saharan Africa (SSA) is one of the regions that depend mainly on agriculture 
but have largely remained food insecure. In fact, food insecurity in SSA has progres-
sively worsened since 1970 with the proportion of malnourished population reaching 
30% in 2017 [1]. Farming in SSA relies on rudimentary methods, which, among 
others, are characterized by continuous tilling of land, which depletes soil nutrients, 
leading to poor soil quality. Many countries in the region are making efforts at rehabil-
itation and expansion of irrigable land, in addition to subsidy on fertilizer and seeds. 
However, intensive use of inputs depletes agriculture’s natural resource base, jeopar-
dizing current and future productivity. More than three-quarters of food is produced 
in this manner on smallholder farms despite serious production challenges including 
degradation and nutrient-deficient soils, soil-borne and plant pathogens and pests, 
unreliable rain-fed farming, high postharvest losses, especially of milk, grains, and 
tubers, resulting from poor processing and storage, poor farming skills, and limited 
access to and utilization of appropriate agricultural technologies. In SSA, studies have 
shown that majority of smallholder farmers lack awareness of improved agricultural 
practices and technical know-how, partly because of weak linkages between research-
ers, extension staff, and farmers [2]. The food production-consumption gap for SSA is 
projected to widen, allowing food insecurity to reach catastrophic levels in the coming 
years as majority of smallholder farmers continue aging, while the youth remain less 
attracted to farming. This will be exacerbated by the projected increase in population 
in the region, with a higher increase than rest of the world (Figure 1).
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The region’s agricultural development is in a race against time to eliminate this 
deficit as climate change is expected to lead to significant reductions in crop yields, 
threatening the livelihoods of millions of poor subsistence farmers and agricultural 
workers [3]. On the other hand, closing the development deficit and providing 
farmers with access to the investment, technologies, and knowledge they need to 
adapt to climate change could transform their development prospects. Increasing 
farm productivity is therefore a priority as yields have stagnated at levels well below 
global averages. It is quite clear that scientific and technological advances could be 
used to mitigate the factors that have continued to keep African agricultural pro-
ductivity at very low levels. Prospects do exist for significant productivity improve-
ment through a combination of technological and policy measures. Improving 
farmers’ access to technology is central to meeting the double challenge of closing 
the development deficit and adapting to climate change. The African Union (AU)’s 
comprehensive approach that envisions a 6% annual growth in agricultural pro-
ductivity requires the deployment of advanced technologies coupled with strong 
policy support. It has been observed that realizing a 6% agricultural productivity 
growth rate will need unprecedented policy support from African governments and 
international development partners [4]. Such policy shifts should aim for sustained 
investment in the generation of agricultural technologies and most particularly 
for the deployment of advanced biotechnologies. “Biotechnology” as a term has 
evolved since it was coined in the early twentieth century and is today defined 
differently by different organizations, groups, and individuals. For example, the US 
National Science Foundation defines it as “The controlled use of biological agents, 
such as microorganisms or cellular components,” while the Food and Agriculture 
Organization of the United Nations (FAO) and the Convention on Biological 
Diversity (CBD) define biotechnology as “any technological application that uses 
biological systems, living organisms or derivatives thereof, to make or modify 
products or processes for specific use.” Generally, therefore, biotechnology is any 
use of organisms or its components in industrial, medical, agricultural and environmen-
tal engineering or processes. The growing human population, coupled with climate 
change, has triggered the need to explore complementary biotechnological innova-
tions for improving food production, better healthcare, and cleaner environment.
Many challenges faced in agriculture can be minimized through the applica-
tion of various biotechnologies. Low production associated with degraded soils, 
drought episodes, emergent plant pathogens and pests, and postharvest losses can 
now be mitigated using suitable biotechnologies that enrich soils, target produc-
tion traits for improved yields, selective breeding, and genetic engineering for 
insect resistance and drought tolerance. Further, biotechnologies now exist for 
overcoming accumulation of aflatoxin, usually produced by certain fungal species 
under moist and dump conditions. Generally, biotechnologies have revolution-
ized farming in industrialized economies, and have the potential to reduce food 
deficits, make farming more remunerative, and attract the youth to agriculture in 
Figure 1. 
World human population compared to Africa, across major timescales. Population in Africa has been and is 
projected to increase more rapidly than rest of the world.
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both middle- and low-income economies. In healthcare, various biotechnologies 
have been developed in the last few decades to manage both infectious and non-
infectious diseases. Diabetes, for example, is now managed using insulin produced 
in bacteria through genetic engineering. To reduce malnutrition, biofortification 
for micronutrients and selective breeding for nutritional improvements have been 
used. In environmental conservation, biotechnologies are applied in removal of 
contaminants such as heavy metals, and waste decomposition. In industrial bio-
technology, biological agents such as microorganisms, tissues, cells, or enzymes 
isolated from living systems have been used, either in the natural state or genetically 
engineered to reduce or remove waste materials from the environment. Others 
involve the use of genetically improved trees for phytoremediation (plant-based 
cleanup of contaminated soils), use of microorganisms to decompose effluent 
(sewage), and the use of biofertilizers and biopesticides instead of chemical sprays. 
Although biotechnology is applied in many fields beyond agriculture, this chapter 
focuses on its integration into agricultural policies of African countries.
2. Regulation and management of biotechnology
Application of biotechnology requires, among others, at least the following to 
be in place: systems that ensure there is adequate capacity to develop and apply the 
technologies; systems that promote research, extension, and wider adoption; and 
systems that regulate the sector to assure sustainable use of resources, environ-
mental and human safety. With growing urbanization and the supply crisis from 
food production deficits, and as more and more people gain interest in agribusi-
ness, there is urgent need to develop guidelines and policies that create a conducive 
climate for agricultural investment while providing safeguards against environmen-
tal and social risks. Although biosafety relates to all biotechnology applications, 
and genetic engineering is just one of the many biotechnologies in use today, most 
discussions about biosafety in many countries worldwide revolve around whether 
a country has projects involving genetic modification (GMO), and hence some 
internationally agreed way of treating safety and associated assessments. The 
GMO-centered handling of biosafety emanates from the erroneous interpretation 
among non-experts that biotechnology = GMO. Biotechnologies (whether low- or 
high-tech) may introduce certain risks. Both modern biotechnology such as genetic 
engineering and traditional techniques commonly used such as crossbreeding 
(with wild counterparts) may confer the same kind of risks but which many people 
generally do not know about. From a scientific perspective, therefore, the controls 
should be the same if the risks (real or perceived) are the same, or nearly same. 
Practically across the world, however, this is not the practice. The level of protection 
required for a product should necessarily relate to its intrinsic characteristics rather 
than to the method of obtaining it, a position taken both by world toxicologists in 
their valuable position paper on genetically modified foods [5].
As a country determines an appropriate level of protection for any product, 
social and political considerations have to be built-in within the scientific decision 
framework in order to calibrate the balance between controls and safety, against 
accessibility/benefits. Agricultural wisdom dictates striking a balance between 
economic development and human as well as environmental health. Thus, an 
enabling policy environment comprises deliberate actions intended to promote 
technology development (such as trained personnel, research and development 
(R&D) infrastructure and R&D funding, efficient extension or advisory services 
that link labs to farms, policies, laws, and regulations for development and applica-
tion of biotechnologies in the sector, among others). Consequently, all products 
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of biotechnology are regulated and undergo risk assessment. For example, seeds 
developed through selective breeding are managed through phytosanitary regula-
tions as well as seed varieties legislations. Risk assessment is a process used every 
day when choices and decisions have to be made, and is the most critical component 
of biosafety implementation. Although risk assessment is necessary for all bio-
technologies applied in agriculture, health, and environmental work, the attention 
appears concentrated on genetic engineering and its products (GMO). The risk 
assessment process used for GMOs closely resembles the assessments made for envi-
ronmental impact. Before a GM crop is released to the market, regulators worldwide 
require these products to undergo rigorous risk assessments to ensure an adequate 
level of safety to humans, animals, and environment. As such, all GMO products 
available in the market today have undergone a risk assessment. Products of genetic 
engineering (GMO) are managed through a more stringent regulatory system, often 
referred to as National Biosafety Frameworks (NBFs). As such, biotechnology poli-
cies for most countries are all about GMO and similar products developed through 
“modern biotechnology”—a term used to refer to more advanced biotechnologies 
that include tissue culture, molecular marker technology, and genetic engineering, 
which generally require laboratories and significant level of skills to perform.
2.1 Global management of biotechnology
One of the decisions of the United Nations Conference on Environment and 
Development (UNCED) in 1992 was the adoption of the Convention on Biological 
Diversity (CBD), to regulate biotechnology (Articles 8 (g) and 19). In response to 
Article 19 (3), a decision was made during the Conference of Parties (COP5) in 1995 
to develop a protocol on biosafety. The Cartagena Protocol on Biosafety (CPB) was a 
direct international legal response to the CBD contributing toward the conservation 
and sustainable use of biological resources. The entry into force of the protocol (2003) 
obligated signatories to the protocol to localize it within their national laws. Current 
intergovernmental mechanisms governing the application of modern biotechnology 
in which African countries actively participate include: (1) The Codex Alimentarius 
Commission, (2) Cartagena Protocol on Biosafety (CPB) to the Convention on 
Biological Diversity (CBD), and (3) Plant Protection Convention (IPPC). Signatories 
to the CPB obligated themselves to localize the protocol within their national laws. So 
far, nearly all SSA countries have ratified or complied with accession requirements of 
the CBD, except for Equatorial Guinea, Liberia, Sierra Leone, and South Sudan.
Within regional trading blocks of SSA, frameworks of action for biotechnology 
require a collective understanding among member states, and a regional framework 
on biosafety. Many regions have made attempts to foster a united framework, 
but none of these have progressed beyond mere intentions. For example, the East 
African Cooperation (EAC) Protocol on Environment and Natural Resources 
(2006) urges partner states to “develop and adopt common policies, laws and take 
measures to ensure that the development, handling, transport, use, transfer and 
release of any living modified organisms are undertaken in a manner that prevents 
or reduces the risks to environment, natural resources and human health” (C 3, 
A 27(1)). However, implementing such a recommendation would first require a 
regional discussion to enable member states to understand current issues, trends, 
challenges, and opportunities for agricultural biotechnology, and to have a collective 
understanding that will catalyze common policies and biosafety regulations, in line 
with the goals of regional integration, and to eliminate some of the non-tariff trade 
barriers associated with transboundary movements of GMOs. At the national level, 
the National Biosafety Frameworks (NBFs) provide the overall policy, legal and 
institutional mechanisms for development, deployment and use of biotechnology.
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2.2 National biosafety framework
A National Biosafety Framework (NBF) is a combination of legal, administra-
tive, and technical instruments put in place to build a country’s competence to 
handle biotechnology research, development, and commercialization. Specific 
components of these instruments are the national biosafety policies, statutes passed 
by parliament and specific regulations linked to the statutes, administrative and 
technical systems for risk assessment, public awareness and participation, decision-
making, enforcement and monitoring. An NBF is also a tool to be used in the 
implementation of the CBP. These frameworks often focus on GMOs, and have been 
generally driven by the crop sector, although they are meant to cover broad bio-
technology research and applications. Although varying from country to country, 
NBFs usually contain a number of common elements, such as policy on biosafety, 
regulatory regime for biosafety, a system to handle notifications or requests for 
authorizations for certain activities, field releases of GMOs into the environment, 
among others. All these involve public participation and risk assessment, a mecha-
nism for monitoring and inspections, and a system for public awareness and public 
information.
The next section appraises the state of enabling policy environment within 
the SSA in the broad sense, examining specific indicators such as: evidence that a 
country has an agency that promotes the application of biotechnologies, support 
for biotechnology development through research funding, support to adoption 
through extension services, existence of policies, laws and regulations, and 
specific agency that regulates the use of biotechnology—how efficiently these 
systems function.
3. State of biotechnology policy environment in SSA
As stated earlier, application of biotechnology requires systems that ensure 
there is adequate capacity to develop and apply the technologies safely; promote 
research, extension, and wider adoption; and regulate the sector to assure sustain-
able use of resources, environmental and human safety. These components together 
include the national biosafety policies, statutes passed by parliament and specific 
regulations linked to the statutes, administrative and technical systems for risk 
assessment, public awareness and participation, decision-making, enforcement 
and monitoring. This section audits the policy environment by assessing indica-
tors and evidence for promotion and support for biotechnology development 
through research funds, support to adoption through extension services, existence 
of policies, laws and regulations, and specific agency that regulates the use of 
biotechnology within each sector (crops, forestry, livestock, and aquaculture) and 
overall across sectors. Scores—ranging from very low or very weak to very high or 
very strong—are assigned to each country based on information (qualitative and 
quantitative) gathered from various sources, which then forms the basis of the 
classification.
3.1 Policy and biosafety frameworks
Countries in SSA are at different levels of development and implementation of 
NBFs. The levels and extents of development of the frameworks largely depend on 
their adherence to, and domestication of, key international agreements, the political 
good will as well as human and financial capacities. SSA countries started putting 
in place biosafety legislation in the 1990s; today, only 18 countries have biosafety 
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Country Biosafety framework (policy, law, 
regulations, guidelines, and institutions)
GE crops
Burkina Faso Has NBF; Act 2006 (revised 2013); Biosafety 
Decree 2004; Biosafety Law 2011; Policy on 
Biotech; National Biosafety Authority
Cowpea; CR of cotton suspended 
in 2016—discussions underway to 
restore with new variety
Cameroon Has NBF; Biosafety Act 2003 (revised 2007); 
Biosafety guidelines 1995
Cotton; no ER of any product
Egypt Legislation under review; robust R&D; past 
commercial release
Wheat, potato; CR of maize 
suspended due to regulatory 
changes in 2012, with all GM
Ethiopia Has framework and R&D; product approved 
for commercial release
Enset, maize, cotton; CR of cotton 
approved in June 2018; maize, 
enset in CFTs
Ghana Act 2011 (Enacted into law 2012); Regulatory 
Communication Strategy 2014; Regulatory 
framework yet to be finalized; Policy on 
Biotech; NBC
Cotton, cowpea, rice; but no ER
Kenya Has NBF; National Biotechnology Policy 
2006; Biosafety Act 2009; 4 biosafety 
Regulation 2011, 2012; National Biosafety 
Authority
Cotton, maize, cassava, banana, 
sweet potato, gypsophila flower, 
sorghum; NPT for cotton 
underway, for maize pending; 
Import ban on GM since 2012
Lesotho Has some elements of NBF; National Biosafety 
bill 2005; amended 2014; National biosafety 
policy; National biosafety awareness strategy 
2013; National Biosafety Council; no research
—
Malawi Has NBF; Act 2002; Biosafety guidelines 
1995; Biosafety regulatory framework 2007; 
National Biotech policy 2008; draft legislation
Banana, cowpea, cotton; NPT for 
cotton advanced; no ER
Mali Has NBF; Biosafety law 2008; Biosafety decree 
2010; National Biosafety Committee; GMO 
research prohibited
—
Mauritius Has elements of NBF; GMO Act 2004; 
Plant Protection Bill 2006; Ministry of Agro 
Industry and Food Security
Sugarcane
Mozambique Has NBF; Biosafety law 2007 (revised 2012); 
draft biosafety regulations; GIIBS; NBC
Maize, cotton; no ER; Bt maize 
ready for ER; Bt/DT stack in CFT
Namibia Has elements of NBF; Biotechnology and 
biosafety policy 1999; Biosafety Act 2006; 
Draft legislation; Biosafety Council of the 
NCRST; no research
—
Nigeria Has NBF; Biosafety bill 2011 (bill still in 
Senate); Biosafety guidelines 2001; National 
Biosafety Management Agency (NBMA)
Cotton, cassava, cowpea, 
sorghum, soybean; CR of cotton 
approved in July 2018
Republic of South 
Africa
Has robust NBF; GMO Act 1997; Biosafety 
guidelines; National Biotechnology Policy and 
Strategy 2001; Directorate of Biosafety
Maize, soybean, cotton, wheat, 
potato, sugarcane; CR for cotton 
in 1997, maize in 1998, and 
soybean in 2001
Sudan Has NBF; Law of Biosafety 2010; National 
Biosafety framework 2008; Sudan National 
Biosafety Council
Cotton; CR of cotton approved 
in 2012
Swaziland Has elements of NBF; Biosafety Act 2012; 
legislation under review
Cotton; CR of cotton approved in 
May 2018
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legislation in place (Table 1). The majority of these (9) were passed in the period 
2006–2010. The extent to which biotechnology has contributed to agricultural 
productivity in various countries is closely linked with, and has been dictated by, 
the policy/political landscape and the nature of legislation enacted to govern the 
technology. The lack of biosafety legislation, biotechnology policies, and absence 
of biosafety procedures in several countries continues to be a major gap and a 
significant impediment and discouragement to research institutions that are willing 
to undertake high-end biotech R&D. This is because the institutions are not able to 
obtain approvals from regulatory authorities, or because processes for application 
are opaque and tedious, and generally the institutional landscape does not encour-
age R&D with significant biotech content.
In terms of ranking for policy environment for development, application, and 
adoption of biotechnology across sectors, Republic of South Africa is comparatively 
very strong in all sectors except fisheries and aquaculture. Five (5) other coun-
tries (Ethiopia, Ghana, Kenya, Nigeria, and Sudan) are “strong” across sectors in 
enabling environment for application of agricultural biotechnologies. Eight (8) 
are medium, while the rest are either weak (8) or very weak (22), as summarized 
in Table 2. In comparison, more than half of the countries in SSA have a weak 
enabling environment in all the sectors. When looked at in terms of two categories, 
as either weak or strong, three-quarters (75%) of the countries cluster in the weak 
category, with only 10 countries appearing as above average or strong. This category 
comprises Botswana, Ghana, Kenya, Malawi, Namibia, Nigeria, South Africa, 
Tanzania, Uganda, and Zimbabwe. Three countries (Ethiopia, Sudan, and Zambia) 
cannot confidently be assigned to either of these two groupings because they clas-
sify with a wide variation across sectors.
Country Biosafety framework (policy, law, 
regulations, guidelines, and institutions)
GE crops
Tanzania Has NBF; Biotech policy 2010; Environment 
Management Act 2004; Biosafety regulation 
2009; National Biosafety Committee; strict 
liability regulations revised in 2015 to allow 
CFTs; strict liability remains if product is 
commercialized
Maize; no ER
Uganda Has NBF; National biosafety bill 2012, (Passed 
2017; referred back to Parliament); Biosafety 
guidelines 1995; Draft Biotech and Biosafety 
Policy 2013; National Biotechnology Policy 
2008; Uganda NCST; National Biosafety 
Committee
Banana, maize, cassava, rice, 
cotton, potato, soybean; no ER
Zambia Has elements of NBF; Biosafety Act 2007 
(revised 2013); National Biosafety Policy 
2013; National Biosafety Authority 2013; no 
research allowed
—
Zimbabwe Has elements of NBF; National Biotech 
Authority Act 2000; Biosafety guidelines 
1998; National Biotechnology Authority; no 
research allowed; cultivation and imports of 
GMO banned
—
GE, genetically engineered; ER, environmental release; CR, commercial release; NPT, national performance trial; 
CFT, confined field trial
Table 1. 
Status of policy environment for biotechnology in some notable SSA countries.
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3.2 Public and private investments
While the formulation of policy and establishment of biosafety frameworks 
are principally a function of the political will of the country, and not necessarily 
resource-endowment, a major aspect of the enabling environment that seems to 
challenge the majority of SSA countries is “resourcing” of biotechnology programs. 
This includes investments in capital items (labs, equipment, etc.), human resources, 
and operations. Although precise value of agricultural biotechnology spending is 
difficult to obtain, estimates (focusing only on crops and livestock) obtained from 
IFPRI’s Agricultural Science and Technology Indicators (ASTI) database (www.
asti.cgiar.org) show that SSA countries invest very limited amounts on agricultural 
R&D generally, and agricultural biotechnology in particular. Staffing levels (FTEs) 
from ASTI data indicate low levels of staffing in the majority of countries. Although 
FTEs (which is only one of the aspects of investment) cannot be used to fairly 
interpret the level of public or private sector investment (because a section of the 
experts may have been trained outside their countries, either through incoming 
scholarships or self-sponsored programs), the low numbers point to a low level of 
public investment. The total agricultural research for development (ARD) spend-
ing takes a similar pattern to policy frameworks, that is, South Africa, Kenya, and 
Nigeria are consistently among the top in terms of ARD spending. As expected, 
private investments in ARD in SSA are mainly directed toward high-value crops and 
non-traditional products such as cut flowers. A recent development is the prolif-
eration of private agribusiness investment funds targeting African agriculture. In 
addition, although progress is slow since Maputo Declaration (in 2003), the posi-
tion as at 2015 (lead up to Malabo Declaration) indicated that some countries have 
taken steps to honor their commitments to increasing investments in agriculture 
and a number of countries have taken a proactive role in attracting private sector 
agribusiness investments by offering various incentives such as tax holidays within 
the first few years of an agribusiness establishment  
(e.g., Nigeria) and zero duty on agricultural machinery (e.g., Ghana, Nigeria).
Other than Republic of South Africa, the other top countries in total ARD 
and biotech spending are Nigeria (96.4 million USD total ARD spending), Kenya 
(50.8 m), Ghana (42.9 m), and Uganda (25.2 m). The figures show that even these 
leading countries spend only modest amounts on biotech (Figure 2). Among 
the other countries spending more than 10 million USD on crop and livestock 
biotech are Burkina Faso, Cote d’Ivoire, Ethiopia, and Zimbabwe, with the rest 
of the countries spending less than 10 million USD (Figure 1). Although many 
countries signed the Maputo Declaration, committing at least 10% of agricultural 
Enabling 
environment
Countries
Very weak Angola, Benin, Burundi, Chad, CAR, Congo, Djibouti, DRC, Eritrea, Gambia, Equatorial 
Guinea, Gabon, Guinea, Guinea Bissau, Lesotho, Liberia, Niger, Togo, Sierra Leone, 
Somalia, South Sudan, Swaziland
Weak Burkina Faso, Cameroon, Cote d’Ivoire, Madagascar, Mauritius, Mozambique, Rwanda, 
Senegal
Medium Botswana, Malawi, Mali, Namibia, Tanzania, Uganda, Zambia, Zimbabwe
Strong Ethiopia, Ghana, Kenya, Nigeria, Sudan
Very strong Republic of South Africa
Table 2. 
Classification of countries on basis of enabling policy environment for biotechnology.
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GDP to R&D, rough estimates suggest that the gross expenditure on R&D for SSA 
is less than 0.3%. In most of the countries, government contribution to National 
Agricultural Research Institutes (NARIs) is inadequate, irregular, and often late [6] 
whereas international donors provide 75% of NARI’s budgets. Overall, an estimated 
40% of SSA countries spend less than 5 million USD on crop and livestock biotech 
a year. It appears that the level of spending on agricultural biotechnology largely 
corresponds to country classifications (Figure 2; Table 2)—where top 10 spenders 
are also the countries predominantly classified in the “Strong” and vice versa even 
though other indices for enabling environment were also used in the classification.
3.3 Collaboration and networking
African countries’ entry into biotechnology has been stimulated by many interre-
lated factors, particularly the cumulative nature of the advancement in biotechnology. 
In addition, the pace at which SSA biotechnological advancement has benefited from 
regional and subregional organizations and networks credited with the development 
of ARD capacity in SSA have also contributed in significant ways to many aspects 
of enabling environment. These include the biotechnology support programs and 
initiatives driven by the Consultative Group on International Agricultural Research 
(CGIAR) whose centers have, for over three decades, worked collaboratively with 
many SSA countries on biotechnology research and application in different sectors 
[7]—with the countries hosting the centers accounting for a relatively larger share 
of this. In the livestock sector, the International Livestock Research Institute (ILRI) 
working in partnership with national and other international partners has made 
strides in developing genetically engineered vaccines while in forestry, the World 
Agroforestry Centre (ICRAF) has provided support in capacity development as 
Figure 2. 
Total ARD versus biotech spending (in USD) in SSA*—absolute, and per million inhabitants (Data obtained 
from ASTI, 2014) *Comparable biotech spending data for Republic of South Africa was unavailable.
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well as research and application of low to medium level forestry biotechnology. It is 
perhaps in the crops sector that the CGIAR centers have made the greatest contribu-
tion, with several centers including ICRISAT, CIMMYT, the International Potato 
Centre (CIP), and IITA contributing substantially in the research and application 
of medium- to high-level biotechnology for maize, potato, cassava, and sorghum, 
among other crops. Further, African regional research organizations such as AGRA 
and AATF, among others, have played a part in research and development as well as 
application of biotechnology especially in the crop sector [7].
There is a close relationship among existing capacities, level of application, and 
enabling policy environment for biotechnology. Higher capacities correspond with 
higher levels of application and enabling policy environment. A relationship cycle 
can explain this observation—a stronger enabling policy environment promotes 
higher capacity and hence enables technology development and application. On the 
other hand, a country cannot regulate “nothing”—a robust biotechnology research 
and application would require and hence catalyze the development of regulation, 
policy, and laws, for example. Policies and legislations on biotechnology in a coun-
try with no research on, or application of, biotechnology is meaningless unless it is 
part of a plan. However, overall, having a critical mass of requisite human capacity 
is the critical starting point.
3.4 Public awareness and political support
Political support for anything, including biotechnology application, is difficult 
to gauge, and has to be inferred, for example, from specific deliberate actions. Based 
on such inferences, therefore, political support for biotechnology application in SSA 
is varied across countries. The presence of a policy and law on biotechnology and 
biosafety can be interpreted as evidence of political support, except cases where these 
laws are enacted to prohibit the use of biotechnology. Due to controversy surround-
ing GMO in agriculture across SSA, there is more public scrutiny of the applica-
tion of this technology. This can explain why the media is awash with articles and 
stories demonstrating, on the one hand, the usefulness of biotechnology to farmers, 
and on the other, skepticisms and outright opposition, specifically to GMO [3]. 
Unfortunately, the perceptions and misrepresentations on GMO are often extended 
to any conversation about agricultural biotechnology as a whole. With the exception 
of South Africa, there are no calibrated national surveys assessing the public under-
standing, perception, and acceptance of biotechnology in Africa. The Agricultural 
Biotechnology Programme of the University of Nairobi has data from an opinion sur-
vey on awareness and willingness to use genetically engineered products, and another 
on actual use of these products in the manufacturing sector. The survey showed more 
than 90% of raw materials for millers and manufacturers in Kenya to be sourced both 
from East Africa and countries such as Southern Africa, USA, Europe, and others 
known to predominantly grow genetically engineered crops such as corn. The South 
African study [8] reveals a very high level of ignorance about biotechnology among 
the general population, and favorable support for biotechnology among the informed 
respondents. Thus, public awareness remains a gap even in countries that rank high in 
the policy environment for agricultural biotechnology. Thus, despite the perception 
that the public is aware about biotechnology and what it can do or not do, much of the 
paranoia can be attributed to lack of understanding, political and business contests.
As explained earlier, development and adoption of agricultural biotechnology 
require both regulatory and promotional systems. Political will and support can 
drive agricultural biotechnology even in the absence of NBFs. One of the latest 
examples where strong political support has been demonstrated is Uganda. In 
Uganda, a Biotechnology and Biosafety Bill, which has been awaiting enactment 
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since 2012, was passed in Parliament in October 2017 but referred back by the 
President for some amendments. It was passed again in 2018, but this time with 
strict liability clauses that will definitely retard biotechnology development in the 
country. However, the country has a presidential order allowing GMO R&D, await-
ing enactment of a biosafety law. Somalia (which has had frequent civil strife since 
1991) has also shown a strong political will—as seen in many laws in draft stage 
but is operational (such as the Veterinary Code—Law No. 34/2006 & 2008 imple-
mented in draft form since 1997). Perhaps the presence of fewer experts (many 
have fled the country) and a less secure environment for foreign experts to operate 
have contributed to the slower pace of policy development to support agricultural 
biotechnology. It is obvious that if a technology is not being applied, then enact-
ment of laws is never urgent. In the neighboring Djibouti, there are some laws and 
regulations, including those aimed at positioning her for adoption of modern bio-
technologies including genetic engineering. However, there lacks specific roadmaps 
for achieving some of the goals envisioned in the legislation.
The Water Efficient Maize for Africa (WEMA) Bt maize adoption in Kenya pro-
vides a context to understand the complex political environments that can impede 
biotech adoption. Kenya is one of the countries with many genetically engineered 
products at various stages of development: Insect-protected Bt maize and Bt cotton 
have both undergone confined field trials (CFTs), and are awaiting the last stages 
before commercialization—National Performance Trials (NPTs). To prepare the 
ground for agricultural technology uptake, the government of Kenya put in place 
legal, structural, and other regulatory frameworks including human capacity to 
manage GMOs by 2009. This heavy investment in legal, human, and infrastructural 
capacity for GM research was expected to improve capacity to develop and manage 
processes for detecting, testing, and assessing the safety of GM foods and products. 
Four regulations that implement the Biosafety Act have been gazetted (2011–2013) 
to ensure compliance with all activities undertaken within a field, introduction 
into the environment, labeling, and import, export, and transit of GMOs. Despite 
this preparedness, the adoption of GM crops and products has been hampered by 
political and regulatory bottlenecks that have delayed farm deployment and entry 
into market systems. In disregard of the provisions of the act and implementing 
regulations, together with existing infrastructure to manage GMO, the country 
imposed a ban on GMO in 2012. This ban has undermined efforts to even conduct 
NPT, a pathway to commercialization of Bt maize.
Apart from its effect on high-tech biotechnologies (genetic engineering—
GMO), lack of political support can hamper even low-end biotechnologies such as 
biopesticides. For example, synthetic chemical pesticide (lindane) was first intro-
duced in Nigeria in the early 1950s. Adverse effects resulting from excessive utiliza-
tion of synthetic chemicals have become widely reported (e.g. [9]). Several studies 
have identified plant-based sources of pesticide in Nigeria, including Cannabis 
sativa, Eucalyptus globules, Balanites aegyptiaca, Khaya senegalensis, Nicotiana 
tabacum [10] and neem leaf water extract, and aqueous tobacco extract [11], and 
demonstrated that tissues from these plants contain bioactive pesticide agents. 
The broad anthology of living and non-living entities present in biopesticides vary 
considerably in their properties, mode of action, fate, composition, and behavior 
within their surroundings. As a result, the government needs to set strict health, 
safety, and environmental monitoring regulations before granting approval for 
the production and handling of biopesticides. However, the lack of governmental 
interest, support, and advocacy, and clear policies on biopesticide development, 
regulation, and implementation in Nigeria has hampered progress, investments, 
development, and accessibility to biopesticides, and has deterred farmers from 
patronizing biopesticides [12].
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4. Gaps and opportunities for biotechnology advancement
This section examines areas or issues constituting either challenges which if 
addressed, or opportunities which if harnessed, will enhance research and commer-
cial applications of agricultural biotechnologies in SSA. Besides selective breeding 
as well as germplasm characterization based on phenotypes, tissue culture in crops, 
clonal propagation in trees, sex reversal in aquaculture, and artificial insemination 
(AI) in livestock, use of modern advanced technologies remains limited in SSA, 
mostly confined to research projects. However, use of molecular and genomic tech-
nologies, while still low, is increasing rapidly especially in research. A major con-
straint to the application of most of these technologies in SSA relates to capacities 
(human resources and facilities) and several dimensions of enabling environment—
especially political will, low public awareness, and associated effect on acceptance, 
lack of financial investments, and limited organizational capacities. Five key gaps 
can be identified for SSA, corresponding to opportunity areas for action: (1) policies 
and biosafety frameworks, (2) awareness and public participation, (3) utilization of 
research products and public-private partnerships (PPPs), (4) human capacity and 
research infrastructure, and (5) financial resources for R&D.
4.1 Biotechnology policies and biosafety frameworks
There is a close relationship between the extents to which biotechnology is being 
deployed in countries and the policy and political environment for biotechnology. As 
stated earlier, the relationship among application, capacity, and enabling environment 
is complex, each somehow acting as driver for the others—with mutually re-enforcing 
effects. Specifically, countries that are consistently ranked high in applications of 
biotechnology have also made progress in developing biotech-specific biosafety 
policies. For high-tech technologies such as genetic modification, the lack of biosafety 
legislation, policies, and biosafety procedures in several countries continues to be a 
significant impediment and discouragement to institutions, including private sector 
institutions that are willing to undertake high-end biotech R&D because processes 
for application are opaque and tedious, and generally the institutional landscape 
does not encourage R&D with significant biotech content. Tanzania, for example, 
has shown a strong political will to promote agricultural biotechnology, as evidenced 
by the National Biotechnology Development Policy, Biosafety Regulations 2009, 
Environmental Management Act, and other policies and laws. However, the country’s 
legal framework is prohibitive. Strict liability and redress provisions in the law and 
regulations are currently a hindrance to advancing biotechnology research and devel-
opment in the country. Djibouti has some laws and regulations, including those aimed 
at positioning her for adoption of modern biotechnologies including genetic engineer-
ing. However, there lacks specific roadmaps for achieving some of the goals envisioned 
in the legislation. Djibouti should focus on creating a favorable policy environment 
to attract private sector working on agricultural biotechnology. Mozambique, on the 
other hand, has enacted several laws, a large majority of which are focused on protect-
ing natural resources. A few plans have been prepared, such as the National Agriculture 
Investment Plan 2014–2018. However, these lack clear roadmaps and time-bound 
actions. While Madagascar has clearly paid attention to policy and legislation side, 
other enablers that can enhance research and applications are still relatively absent.
4.2 Public awareness and participation
There are major gaps in public awareness and understanding of the science, and 
the potential promise and usefulness of biotechnology in African agriculture. There 
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are also knowledge gaps, with misinformation on risks and perceptions of risks 
remaining one of the key factors that have hindered the adoption of biotechnology 
in Africa. Consequently, there are misconceptions and lack of knowledge about bio-
technology in general, and about GMOs in agriculture in particular. Although there 
have been successes in public awareness creation, there are still gaps in policy sup-
port, political commitment, and acceptance of genetic engineering technologies, 
and this continues to hinder the adoption of certain biotechnologies in agriculture.
4.3 Utilization of research products and public-private partnerships
The process by which biotech research translates to (commercial) applications 
in the field requires early engagement of industry (private sector players). On the 
other hand, agricultural biotech research in almost all SSA countries is still primar-
ily driven by NARI and university scientists who either have limited knowledge on 
or drive to commercialize research products. Indeed, the incentive of the majority 
scientists seems to be more about the science and the academic products of science 
(in form of publications and patents). There is limited or no incentive to invest 
efforts in commercialization, and the research funding mechanisms do not nor-
mally include the commercialization phase and modalities for it. At the same time 
public extension services are generally weak. Although public-private partnerships 
(PPPs) have been recognized as one of the ways to drive the conversion of biotech 
research into practical use, and despite the fact that there are a number of PPPs 
operating in some countries, there remain major gaps in operationalizing the con-
cept and developing functional partnerships at scale. Simple PPP models have been 
used in delivery of animal health and AI services in some countries—for example, 
where semen and vaccine production is done by public sector and field delivery 
done by private sector, including farmers’ organizations and cooperatives. Where 
new technologies and innovations are involved, a major gap in PPPs is the issue of 
proprietary rights, especially patents, intellectual property rights, and sharing of 
benefits accruing from joint biotechnology research and development activities.
4.4 Human capacity and research infrastructure
In most SSA countries, there is a clear lack of a critical mass of scientists in areas 
relevant for agricultural biotechnology. Even countries that rank as relatively “high” 
in capacities do not necessarily have critical mass in the more “advanced” areas of 
modern biotechnology such as genomics, and genetic engineering, for example. 
The majority of SSA national agricultural research systems (NARS) have research 
programs that are often limited in scope and dependent on a handful of scientists. 
Due also to the financial and infrastructural constraints, many such programs 
often have limited national capacities to implement initiatives beyond pilot scales. 
This calls for innovative ways of forming critical mass of research teams across 
sectors—working around issues that allow sharing of staff (and facilities). The 
acquisition and maintenance of the expensive infrastructure needed for high-tech 
applications remain a challenge for most countries. Facilities in several countries 
(the low-capacity countries) are too basic to support modern biotech research. In 
other cases, equipment acquired through projects only function during the life of 
these projects and thereafter cannot be maintained—due to budget constraints. The 
lack of engineers and technicians trained to service these fast-evolving and sophis-
ticated equipments presents another challenge, as do inadequate power supplies and 
frequent power outages, which also affect reliable cold chains—such as for AI and 
vaccine field delivery. These challenges have informed the establishment of regional 
shared biotechnology platforms such as the BecA-ILRI Hub; the concept of shared 
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facilities is, in the short- to medium term, seen as a means of gradually supporting 
the strengthening of capacities in the biotechnology fields in SSA. In SSA, the four 
agricultural sectors—crops, forestry, livestock, and fisheries/aquaculture—are not 
necessarily under the same ministry. Indeed, in some countries all of these sectors 
are in different government ministries—although finding livestock and crops under 
the same ministry is increasingly more common. The administrative separation of 
these sectors, combined with poor cross-sectoral coordination is inimical to effi-
ciency in the development of technologies. It limits consolidation and exploitation 
of synergies across sectors owing to bureaucratic procedure required to share physi-
cal and human resources—such as labs and personnel. For most countries, sharing 
of these resources across ministries is just not practiced at all. Even mobilization of 
resources is done separately by sector, and the amounts allocated to the “hosting 
ministry” do not always reflect the needs. The countries also need to establish and/
or strengthen biotechnology R&D multisectoral networks at national levels and 
explore mechanisms for linking these to subregional and continental initiatives in 
order to leverage resources, create synergies, and avoid duplication (hence, enhance 
efficiency), facilitate learning, horizontal and transboundary transfer of technolo-
gies, and upscale best practices and technologies.
4.5 Financial resources for R&D
The main challenge for public agricultural biotechnology R&D in SSA remains 
how to mobilize investment capital (beyond what is needed for personnel and 
infrastructure) to initiate or sustain research (and facilitate the process of taking 
findings to commercial use). Although there has been some growth in the level 
of funding to ARD in some countries, the level of financing is still extremely low, 
especially for biotechnology, and not allowing countries to engage effectively in 
cutting-edge biotech research. Most of the current biotechnology R&D programs 
are donor funded—with very limited domestic investments; in most countries 
the allocation is only for salaries (for the limited number of biotech personnel). 
Although precise value of agricultural biotechnology spending is difficult to obtain, 
estimates made on the basis of 2014 sector figures (focusing only on crops and live-
stock) obtained from ASTI database show that most countries invest very limited 
amounts on agricultural biotechnology. Mobilization of resources (from domestic 
and other sources) for agricultural biotech is clearly a major area that governments 
need to look at. In the meantime, given the high cost of biotech R&D, available 
investments need to be used in a much more coordinated manner to achieve effi-
ciencies from scale and complementarity—and hence the need for cross-sector 
coordination in biotech R&D. Despite the clear dominance of the public sector both 
in the financing and implementation of agricultural research, the unstable fund-
ing of ARD to date suggests that other avenues should be explored. Universities in 
SSA, for example, are an underutilized resource that could greatly increase research 
output with just slight increases in targeted funding to them.
5. Conclusions
Application of biotechnology in agriculture has increased in recent years due 
to unrelenting effect of climate change exacerbated by a rapidly growing popula-
tion. Countries that have adopted biotechnology in their agricultural systems, for 
example, have significantly improved yields and other farm-level benefits. Safety of 
biotechnology and particularly products of genetic engineering is assured through 
rigorous safety assessments conducted within national and international biosafety 
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frameworks. However, lack of awareness on these processes has slowed the adoption 
of GMO in some countries, especially those with a weak policy environment for 
biotechnology. It appeared that the enabling policy and regulatory environment is, 
in early phases, principally driven and shaped by the demand (applications)—and 
not just the existence of capacity. That is, it starts and evolves at a pace that reflects 
the level of vibrancy on the “applications.” In other words, governments could 
develop the required frameworks but they will serve very little purpose and will 
not “evolve” if they are not being subjected to real tests through active applications. 
Although it is envisaged that existence of biosafety framework would catalyze bio-
tech adoption, the Kenya Bt maize situation and similar examples have shown that 
legal frameworks alone are insufficient to guarantee an enabling policy environ-
ment for investment in remunerative agriculture through biotech crops. Countries 
in SSA adopting biotechnology may require a comprehensive approach that includes 
anchoring biosafety laws in their constitutions and a strong political will to drive 
the agenda. Other focus areas are summarized under Section 4. It is emphasized 
that countries have to deliberately promote public understanding and awareness on 
modern biotechnology, vigorously improve resourcing for biotechnology develop-
ment and adoption, including greater private sector engagement, and improve the 
available research infrastructure and human resources.
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